Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles

Human Reproduction

Volumn 23, Issue 1, 2008, Pages 160-167

  Lee, Tsung Hsien ^a,b   Liu, Chung Hsien ^b   Huang, Chuin Chia ^c,d   Wu, Yi Ling ^b,c   Shih, Yang Tse ^b   Ho, Hong Nerng ^a   Yang, Yu Shih ^a   Lee, Maw Shang ^b,c,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Lee Women's Hospital   (Taiwan)

^d CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anti M llerian hormone; Controlled ovarian stimulation; Estradiol; Ovarian hyperstimulation syndrome

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN; CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; BODY MASS; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OOCYTE; OVARY FUNCTION; OVARY HYPERSTIMULATION; PREDICTION; PROSPECTIVE STUDY; RELIABILITY; RISK; RISK FACTOR; SENSITIVITY AND SPECIFICITY; AGE; BLOOD; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREDICTION AND FORECASTING; PREGNANCY; STATISTICAL MODEL;

ADULT; AGE FACTORS; ANTI-MULLERIAN HORMONE; BODY MASS INDEX; CHORIONIC GONADOTROPIN; COHORT STUDIES; ESTRADIOL; FEMALE; HUMANS; LOGISTIC MODELS; OOCYTE RETRIEVAL; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREDICTIVE VALUE OF TESTS; PREGNANCY; PROSPECTIVE STUDIES; REPRODUCTIVE TECHNIQUES, ASSISTED; SENSITIVITY AND SPECIFICITY;

EID: 40549085015     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem254     Document Type: Article

References (36)

1. Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod 2003;18:1140-1141.
2. Chen CD, Wu MY, Chao KH, Chen SU, Ho HN, Yang YS. Serum estradiol level and oocyte number in predicting severe ovarian hyperstimulation syndrome. J Formos Med Assoc 1997;96:829-834.
3. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:1037-1042.
4. Chuang CC, Chen CD, Chao KH, Chen SU, Ho HN, Yang YS. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertil Steril 2003;79:63-68.
5. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002;77:141-146.
6. Cook CL, Siow Y, Taylor S, Fallat ME. Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000;73:859-861.
7. Delvigne A, Dubois M, Battheu B, Bassil S, Meuleman C, De Sutter P, Rodesch C, Janssens P, Remacle P, Gordts S et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993;8:1361-1366.
8. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891-4899.
9. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction 2002;124:601-609.
10. Fanchin R, Schonauer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 2003a;18:328-332.
11. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003b;18:323-327.
12. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592-596.
13. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-440.
14. Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Anti-Mullerian hormone and its role in ovarian function. Mol Cell Endocrinol 2003;211:85-90.
15. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057- 4063.
16. Hendriks DJ, Klinkert ER, Bancsi LFJM, Looman CWN, Habbema JDF, te Velde ER, Broekmans FJ. Use of stimulated serum estradiol measurements for the prediction of hyeprrespinse to ovarian stimulation in in vitro fertilization (IVF). J Assist Reprod Genet 2004;21:65-72.
17. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, Volpe A. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 2004;19:2738-2741.
18. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21:3103-3107.
19. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22:766-771.
20. Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil Steril 2005;83:1700-1707.
21. Lee TH, Chen CD, Tsai YY, Chang LJ, Ho HN, Yang YS. Embryo quality is more important for younger women whereas age is more important for older women with regard to in vitro fertilization outcome and multiple pregnancy. Fertil Steril 2006;86:64-69.
22. Mathur RS, Joels LA, Akande AV, Jenkins JM. The prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1996;103:740-746.
23. McGee EA, Smith R, Spears N, Nachtigal MW, Ingraham H, Hsueh AJ. Mullerian inhibitory substance induces growth of rat preantral ovarian follicles. Biol Reprod 2001;64:293-298.
24. Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod 1995;10:811-814.
25. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006;85:1541-1543.
26. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-261.
27. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 2003;18:665-667.
28. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005;20:636-641.
29. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112-120.
30. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, Carmona F, Vanrell JA, Balasch J. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 2005;20:915- 922.
31. Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993;8:653-659.
32. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468-471.
33. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 2007;87:223-226.
34. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen AP. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-3071.
35. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979-987.
36. Varma TR, Patel RH. Ovarian hyperstimulation syndrome. A case history and review. Acta Obstet Gynecol Scand 1988;67:579-584.